Challenges and characteristics of thenew clinical trials model within COVID-19 pandemic

Abstract

This paper aims to analyze the impact of the COVID-19 pandemic on the clinical trials. And shed the light on the companies adaptation strategies to the new restrictions on labs research activities by considering uncertainty issue and the experiments challenges. Furthermore it describes the features of the new model based on extending the digital technology usage within the pharmaceutical research domain.

The study uses both descriptive and analytical approachs by refering to gouvernmental, international organizations in addition of researches institutions datasources which concern the health and pharmaceutical industry.

Finally, the study first concluded to a general impact of the Covid 19 pandemic on the pharmaceutical industry in both short and long terms, and second special impacts related to research and development. The study also stipulates that global pharmaceutical companies tend to restructure clinical trials process, as a strategic reaction, to limit the Covid 19 virus spreading by designing decentralized clinical trials, reviewing the volunteer patients hiring process, providing remote patient monitoring solutions, creating virtual control arms and real-world evidence, as well as optimizing the clinical trials supply chain